STOCK TITAN

[SCHEDULE 13G/A] Vor Biopharma Inc. Amended Passive Investment Disclosure

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G/A

Rhea-AI Filing Summary

VOR Biopharma Inc. received an updated ownership report from Paradigm BioCapital entities and related persons on an amended Schedule 13G. Paradigm BioCapital Advisors LP, its general partner, Senai Asefaw, M.D., and Paradigm BioCapital International Fund Ltd. together report beneficial ownership of 1,750,000 shares of VOR Biopharma common stock.

This stake represents 4.5% of the outstanding common stock, based on 38,720,196 sharesDecember 31, 2025. The Paradigm BioCapital International Fund Ltd. itself directly holds 1,546,061 shares, or 4.0% of the class. The reporting group certifies that the securities were not acquired to change or influence control of VOR Biopharma.

Positive

  • None.

Negative

  • None.





Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)






SCHEDULE 13G





SCHEDULE 13G




Comment for Type of Reporting Person: limited liability company


SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G



Paradigm BioCapital Advisors LP
Signature:/s/ David K. Kim
Name/Title:David K. Kim / Authorized Signatory
Date:02/17/2026
Paradigm BioCapital Advisors GP LLC
Signature:/s/ David K. Kim
Name/Title:David K. Kim / Authorized Signatory
Date:02/17/2026
Senai Asefaw, M.D.
Signature:/s/ Senai Asefaw, M.D.
Name/Title:N/A
Date:02/17/2026
Paradigm BioCapital International Fund Ltd.
Signature:/s/ David K. Kim
Name/Title:David K. Kim / Authorized Signatory
Date:02/17/2026
Vor Biopharma Inc.

NASDAQ:VOR

VOR Rankings

VOR Latest News

VOR Latest SEC Filings

VOR Stock Data

530.62M
2.63M
Biotechnology
Biological Products, (no Diagnostic Substances)
Link
United States
BOSTON